DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

Silvio Danese, Gert Van Assche, Chris O’Brien et al.|Journal of Crohn s and Colitis|2019

Cited by 8